CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of EUR 875.04 million. The enterprise value is 495.72 million.
Market Cap | 875.04M |
Enterprise Value | 495.72M |
Important Dates
The next estimated earnings date is Friday, August 15, 2025.
Earnings Date | Aug 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | 225.16M |
Shares Outstanding | n/a |
Shares Change (YoY) | +0.20% |
Shares Change (QoQ) | +0.31% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 125.70M |
Valuation Ratios
The trailing PE ratio is 4.84.
PE Ratio | 4.84 |
Forward PE | n/a |
PS Ratio | 1.67 |
PB Ratio | 1.35 |
P/TBV Ratio | 1.41 |
P/FCF Ratio | 5.94 |
P/OCF Ratio | 5.57 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.13, with an EV/FCF ratio of 3.37.
EV / Earnings | 2.74 |
EV / Sales | 1.00 |
EV / EBITDA | 2.13 |
EV / EBIT | 2.29 |
EV / FCF | 3.37 |
Financial Position
The company has a current ratio of 7.65, with a Debt / Equity ratio of 0.06.
Current Ratio | 7.65 |
Quick Ratio | 7.33 |
Debt / Equity | 0.06 |
Debt / EBITDA | 0.15 |
Debt / FCF | 0.25 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 33.04% and return on invested capital (ROIC) is 24.37%.
Return on Equity (ROE) | 33.04% |
Return on Assets (ROA) | 19.93% |
Return on Invested Capital (ROIC) | 24.37% |
Return on Capital Employed (ROCE) | 33.54% |
Revenue Per Employee | 579,314 |
Profits Per Employee | 199,840 |
Employee Count | 983 |
Asset Turnover | 0.73 |
Inventory Turnover | 4.85 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.82% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +3.82% |
50-Day Moving Average | 3.13 |
200-Day Moving Average | 3.02 |
Relative Strength Index (RSI) | 58.70 |
Average Volume (20 Days) | 60,565 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 7.23 |
Income Statement
In the last 12 months, CureVac had revenue of EUR 523.70 million and earned 180.66 million in profits. Earnings per share was 0.80.
Revenue | 523.70M |
Gross Profit | 458.88M |
Operating Income | 228.37M |
Pretax Income | 209.11M |
Net Income | 180.66M |
EBITDA | 240.86M |
EBIT | 228.37M |
Earnings Per Share (EPS) | 0.80 |
Balance Sheet
The company has 438.33 million in cash and 37.38 million in debt, giving a net cash position of 400.95 million.
Cash & Cash Equivalents | 438.33M |
Total Debt | 37.38M |
Net Cash | 400.95M |
Net Cash Per Share | n/a |
Equity (Book Value) | 646.69M |
Book Value Per Share | 2.87 |
Working Capital | 407.81M |
Cash Flow
In the last 12 months, operating cash flow was 157.03 million and capital expenditures -9.73 million, giving a free cash flow of 147.31 million.
Operating Cash Flow | 157.03M |
Capital Expenditures | -9.73M |
Free Cash Flow | 147.31M |
FCF Per Share | n/a |
Margins
Gross margin is 87.62%, with operating and profit margins of 43.61% and 34.50%.
Gross Margin | 87.62% |
Operating Margin | 43.61% |
Pretax Margin | 39.93% |
Profit Margin | 34.50% |
EBITDA Margin | 45.99% |
EBIT Margin | 43.61% |
FCF Margin | 28.13% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.20% |
Shareholder Yield | n/a |
Earnings Yield | 20.65% |
FCF Yield | 16.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of 3.87.
Altman Z-Score | 3.87 |
Piotroski F-Score | n/a |